SQZ insider filings

SQZ Biotechnologies Co — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-06-15. Screen SQZ transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for SQZ between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — SQZ Biotechnologies Co

FiledFormInsiderReported transactionsSource
2023-06-154SCHEGERIN MARC — DirectorGrant/award (A): 39,875 (derivative) @ $0EDGAR
2023-06-154Jensen Klavs F. — DirectorGrant/award (A): 39,875 (derivative) @ $0EDGAR
2023-06-154Garg Pushkal — DirectorGrant/award (A): 39,875 (derivative) @ $0EDGAR
2023-06-154Elia Marc — DirectorGrant/award (A): 39,875 (derivative) @ $0EDGAR
2023-06-154Coulie Bernard — DirectorGrant/award (A): 39,875 (derivative) @ $0EDGAR
2023-06-154BOLNO PAUL — DirectorGrant/award (A): 39,875 (derivative) @ $0EDGAR
2023-06-154Srivastava Sapna — DirectorGrant/award (A): 39,875 (derivative) @ $0EDGAR
2023-06-154VINK PATRICK V.J.J. — DirectorGrant/award (A): 39,875 (derivative) @ $0EDGAR
2023-06-154SCHULMAN AMY W — Director, 10% ownerGrant/award (A): 39,875 (derivative) @ $0EDGAR
2023-01-264Capasso Richard — See RemarksGrant/award (A): 213,000 (derivative) @ $0EDGAR
2023-01-264Warren Marshelle Smith — Chief Medical OfficerGrant/award (A): 261,000 (derivative) @ $0EDGAR
2023-01-264First David — Chief People OfficerGrant/award (A): 200,000 (derivative) @ $0EDGAR
2023-01-264Knopf Lawrence J — General CounselGrant/award (A): 227,000 (derivative) @ $0EDGAR
2023-01-264BERNSTEIN HOWARD PHD MD — Interim Chief Executive Office, DirectorGrant/award (A): 830,000 (derivative) @ $0EDGAR
2022-08-164Capasso Richard — See RemarksSale (S): 1,183 @ $3.33EDGAR
2022-07-134Zajic Micah — Chief Financial OfficerGrant/award (A): 10,000 (derivative) @ $0EDGAR
2022-07-054Sharei Armon — President and CEO, DirectorGrant/award (A): 2,436 @ $2.70EDGAR
2022-07-054Capasso Richard — See RemarksGrant/award (A): 1,183 @ $2.70EDGAR
2022-07-054Knopf Lawrence J — General CounselGrant/award (A): 1,484 @ $2.70EDGAR
2022-06-164Garg Pushkal — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR
2022-06-164BOLNO PAUL — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR
2022-06-164Jensen Klavs F. — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR
2022-06-164SCHEGERIN MARC — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR
2022-06-164Elia Marc — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR
2022-06-164Coulie Bernard — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR
2022-06-164Srivastava Sapna — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR
2022-06-164VINK PATRICK V.J.J. — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR
2022-06-164SCHULMAN AMY W — Director, 10% ownerGrant/award (A): 20,000 (derivative) @ $0EDGAR
2022-06-034Warren Marshelle Smith — Chief Medical OfficerGrant/award (A): 200,000 (derivative) @ $0EDGAR
2022-05-274Jensen Klavs F. — DirectorPurchase (P): 14,326 @ $3.52EDGAR
2022-02-154Zajic Micah — Chief Business OfficerGrant/award (A): 80,000 (derivative) @ $0EDGAR
2022-02-154First David — Chief People OfficerGrant/award (A): 66,000 (derivative) @ $0EDGAR
2022-02-154Capasso Richard — See RemarksGrant/award (A): 42,000 (derivative) @ $0EDGAR
2022-02-154Sharei Armon — President and CEO, DirectorGrant/award (A): 395,000 (derivative) @ $0EDGAR
2022-02-154Knopf Lawrence J — General CounselGrant/award (A): 97,000 (derivative) @ $0EDGAR
2022-02-154BERNSTEIN HOWARD PHD MD — Chief Scientific OfficerGrant/award (A): 195,000 (derivative) @ $0EDGAR
2022-01-134Sharei Armon — President and CEO, DirectorOption exercise (M): 13,000 @ $1.81 · Option exercise (M): 13,000 (derivative) @ $1.81EDGAR
2022-01-044Sharei Armon — President and CEO, DirectorGrant/award (A): 1,686 @ $7.59EDGAR
2022-01-044Knopf Lawrence J — General CounselGrant/award (A): 454 @ $7.59EDGAR
2021-12-234SCHULMAN AMY W — Director, 10% ownerOption exercise (M): 10,091 @ $2.02 · Option exercise (M): 7,458 @ $4.59 · Option exercise (M): 6,581 @ $4.59 · Option exercise (M): 10,091 (derivative) @ $0 · Option exercise (M): 7,458 (derivative) @ $0 · Option exercise (M): 6,581 (derivative) @ $0EDGAR
2021-12-224Sharei Armon — President and CEO, DirectorOption exercise (M): 11,049 @ $1.81 · Option exercise (M): 11,049 (derivative) @ $0EDGAR
2021-12-154SCHULMAN AMY W — Director, 10% ownerPurchase (P): 1,850 @ $10.88 · Purchase (P): 1,850 @ $10.94EDGAR
2021-07-014Coulie Bernard — DirectorGrant/award (A): 21,000 (derivative) @ $0EDGAR
2021-07-014VINK PATRICK V.J.J. — DirectorGrant/award (A): 21,000 (derivative) @ $0EDGAR
2021-06-174SCHEGERIN MARC — DirectorGrant/award (A): 10,500 (derivative) @ $0EDGAR
2021-06-174Garg Pushkal — DirectorGrant/award (A): 10,500 (derivative) @ $0EDGAR
2021-06-174Jensen Klavs F. — DirectorGrant/award (A): 10,500 (derivative) @ $0EDGAR
2021-06-174BOLNO PAUL — DirectorGrant/award (A): 10,500 (derivative) @ $0EDGAR
2021-06-174Srivastava Sapna — DirectorGrant/award (A): 10,500 (derivative) @ $0EDGAR
2021-06-174SCHULMAN AMY W — Director, 10% ownerGrant/award (A): 10,500 (derivative) @ $0EDGAR

Recent 8-K events — SQZ Biotechnologies Co

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2023-12-228-K1.01 — Entry into a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
2023-10-028-K?
2.06 — Material Impairments
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
EDGAR
2023-09-158-K1.02 — Termination of a Material Definitive AgreementEDGAR
2023-07-258-K8.01 — Other EventsEDGAR
2023-07-078-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
9.01 — Financial Statements and Exhibits
EDGAR
2023-07-038-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
8.01 — Other Events
EDGAR
2023-06-158-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
5.07 — Submission of Matters to a Vote of Security Holders
8.01 — Other Events
EDGAR
2023-04-108-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersEDGAR
2023-01-188-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2022-12-068-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=SQZ returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs